The global auto-injector market is expected to grow significantly over the forecast period. The market held an estimated valuation of USD 37.44 million in 2018 and is projected to account for USD 125.32 million by 2025 at a CAGR of ~22.0% over the forecast period.
The increasing availability of generic auto-injectors and the growing geriatric population are likely to drive the growth of the market during the forecast period.
Furthermore, auto-injectors are more effective and less painful in comparison to syringes; these also provide more control and accurate drug delivery as compared to manual injection. These factors also contribute to the growth of the market.
However, the availability of alternatives such as continuous glucose monitoring devices can hinder the market growth over the forecast period.
Segmentation
The global auto-injector market has been segmented based on product type, application, distribution channel, end user, and region.
The global auto-injector market, by product type, has been segmented into disposable and reusable.
On the basis of application, the global auto-injector market has been classified as anaphylaxis, multiple sclerosis, diabetes, allergies, rheumatoid arthritis, and others.
Based on distribution channel, the global auto-injector market has been segmented into online retailer, pharmacy, and rectal.
By end user, the global auto-injector market has been segmented into home care settings, hospitals & clinics, and ambulatory surgical centers.
Key Players
Some of the key players in the global auto-injector market are Bayer AG, Haselmeier, Novartis AG, Owen Mumford Ltd, Becton, Dickinson and Company, AbbVie Inc., Johnson & Johnson, Amgen Inc., Teva Pharmaceuticals USA, Biogen, Eli Lilly and Company, Mylan NV, Ypsomed AG, Merck KGaA, AstraZeneca, and Kaleo, Inc.
Market Segmentation
Global Auto-Injector Market, by Product Type
Global Auto-Injector Market, by Application
Global Auto-Injector Market, by Distribution Channel
Global Auto-Injector Market, by End User